The Action Profile of Lispro Is Not Blunted by Mixing in the Syringe With NPH Insulindoi:10.2337/diacare.21.12.2098S E JosephA Korzon BurakowskaJames WoodworthStephanie Amiel
MD Jensen - 《Journal of Clinical Investigation》 被引量: 581发表: 1995年 Insulin lispro: a review of its use in the management of diabetes mellitus. As a result of its shorter duration of action, insulin lispro is associated with lower postprandial, but higher postabsorptive and preprandial ...
InsulinPreparation Onset of Action Peak Action Duration of Action Rapid-acting Lispro, aspart, glulisine† 5–15 minutes 45–75 minutes 3–5 hours Inhaled regular < 15 minutes 50 minutes 2–3 hours Short-acting Regular† 30–60 minutes ...
Insulin lispro Amitriptyline may decrease the hypoglycemic activities of Insulin lispro. Insulin pork Amitriptyline may decrease the hypoglycemic activities of Insulin pork. Interferon alfa-2a The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-2a. Interferon alfa-2b The meta...
Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Sirolimus. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Sirolimus. Interferon alfa-2a The risk or severity of adverse effects can be increas...
U-100, pH-Neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes Aims: VIAject庐 is a formulation of human insulin with a very fast onset of action. Previous studies used VIAject in a concentration of 25 U/ml and a pH of... L...
BIOD-531,a U-400 formulation of recombinant human insulin,EDTA,citrate and MgSO_4,is associated with an accelerated onset of action compared to Regular Human Insulin U-500(U-500R)and Insulin Lispro Mix75/25 and has a basal duration profile in obese non-diabetic subjects and in diabetic swi...
Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro Diabetes Obes Metab, 2 (2000), pp. 39-46 View in ScopusGoogle Scholar [141] S.L. Pohar, J.A. Johnson Health care utilization and costs in Saskatchewan’...
A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. To compare the effects of insulin lispro (LP) and human regular insulin (HR) when given twice daily with NPH insulin on glycemic control (...
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012;14(3):218–24. CAS PubMed Google Scholar Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, et al. U-100, ...